Ortho Regenerative Technologies Appoints New CFO

Ortho Regenerative Technologies Inc. (Ortho RTi) announced the appointment of Luc Mainville as senior vice president and chief financial officer, with overall responsibility for operational finance, financial reporting, budgeting, and strategic planning, as well as helping to manage the Corporation’s relationships and interactions with the investment community. Mainville succeeds Ortho RTi’s interim CFO, Benedek Simo, who will remain as Corporate Controller.
 
“We are delighted to have Luc join Ortho RTi at this important time in its corporate and clinical development,” said Brent Norton, president and CEO, Ortho RTi. “Being able to attract someone of Luc’s caliber to this role is a clear testament to the quality of our science and the potential market opportunity for our products under development. His significant operational experience will be a particularly valuable asset as we implement the last phase of our pre-IND program and pursue joint development initiatives with interested industry players for our lead product, Ortho-R.”
 
Mainville has an accomplished history of financial and operational leadership successes within the life science industry. In an executive management career that spans more than 20 years, he has led or been integrally involved in four go-public transactions, completed more than 20 public financings, and managed more than 50 licensing, merger and acquisition, and sale transactions. Mainville also serves as senior vice president and CFO for Valeo Pharma. His earlier experience includes senior management and financial roles at various life science companies, including Acerus Pharma, Cardiome Pharma Corp., Neopharm Labs Inc., and LAB Research Inc. Prior to launching his career in the life science industry, Mainville was a Partner at KPMG LLP. Mainville has served as Vice-Chairman of BIOTECanada and holds an MBA from McGill University.